Search

Search results

267 results found

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

Publication: Journal Article

Yu, C., A. M. Mannan, G. M. Yvone, K. N. Ross, Y. L. Zhang, M. A. Marton, B. R. Taylor, et al. 2016. “High-Throughput Identification of Genotype-Specific Cancer Vulnerabilities in Mixtures of Barcoded Tumor Cell Lines”. Nat Biotechnol 34: 419-23.

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Publication: Journal Article

Parikh, A. R., I. Leshchiner, L. Elagina, L. Goyal, C. Levovitz, G. Siravegna, D. Livitz, et al. 2019. “Liquid versus Tissue Biopsy for Detecting Acquired Resistance and Tumor Heterogeneity in Gastrointestinal Cancers”. Nat Med 25: 1415-21.

A method for high-throughput gene expression signature analysis

Publication: Journal Article

Peck, D., E. D. Crawford, K. N. Ross, K. Stegmaier, T. R. Golub, and J. Lamb. 2006. “A Method for High-Throughput Gene Expression Signature Analysis”. Genome Biol 7: R61.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

Publication: Journal Article

Pikman, Y., B. H. Lee, T. Mercher, E. McDowell, B. L. Ebert, M. Gozo, A. Cuker, et al. 2006. “MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis With Myeloid Metaplasia”. PLoS Med 3: e270.

Retraction Note: Selective killing of cancer cells by a small molecule targeting the stress response to ROS

Publication: Journal Article

Raj, L., T. Ide, A. U. Gurkar, M. Foley, M. Schenone, X. Li, N. J. Tolliday, et al. 2018. “Retraction Note: Selective Killing of Cancer Cells by a Small Molecule Targeting the Stress Response to ROS”. Nature 561: 420.

Multiclass cancer diagnosis using tumor gene expression signatures

Publication: Journal Article

Ramaswamy, S., P. Tamayo, R. Rifkin, S. Mukherjee, C. H. Yeang, M. Angelo, C. Ladd, et al. 2001. “Multiclass Cancer Diagnosis Using Tumor Gene Expression Signatures”. Proc Natl Acad Sci U S A 98: 15149-54.

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Publication: Journal Article

Slabicki, M., Z. Kozicka, G. Petzold, Y. D. Li, M. Manojkumar, R. D. Bunker, K. A. Donovan, et al. 2020. “The CDK Inhibitor CR8 Acts As a Molecular Glue Degrader That Depletes Cyclin K”. Nature 585: 293-97.

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling

Page

https://depmap.org/repurposing/

Rishi Puram

Person: Postdoctoral Fellow

I am a postdoctoral fellow in the Golub lab using functional genomics and chemical screening approaches to define mechanism of action of epigenetic therapy in hematologic malignancies.

Research

Page